Use of anticancer drugs during pregnancy.
D000477:Alkylating Agents / Q000009:adverse effects; D000630:Aminopterin / Q000009:adverse effects; D000818:Animals; D000963:Antimetabolites / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002066:Busulfan / Q000009:adverse effects; D002699:Chlorambucil / Q000009:adverse effects; D002822:Choriocarcinoma / Q000188:drug therapy; D003078:Colchicine / Q000009:adverse effects; D005260:Female; D005313:Fetal Death / Q000139:chemically induced*; D005493:Folic Acid Antagonists; D005865:Gestational Age; D006801:Humans; D015122:Mercaptopurine / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D014520:Urethane / Q000009:adverse effects; D014747:Vinblastine / Q000009:adverse effects
D000477:Alkylating Agents; D000963:Antimetabolites; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D009588:Nitrogen Mustard Compounds; D002699:Chlorambucil; D014520:Urethane; D014747:Vinblastine; D015122:Mercaptopurine; D002066:Busulfan; D000630:Aminopterin; D003078:Colchicine; D008727:Methotrexate